News and Press Releases
Press releases
Theralase® Granted Canadian Cancer Vaccine Patent
Press ReleaseApril 5th, 2024, Theralase® granted Canadian patent for a new cancer vaccine titled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic Treatment with Metal-Based Coordination Complexes and Immunotherapy Method Using Same”....
Theralase® Release’s 4Q2023 Interim Financial Statements
Press ReleaseMarch 27, 2024 - Theralase released the Company’s audited annual consolidated 2023 financial statements (“Financial Statements”)....
Theralase® to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
Press ReleaseV.TLT | March 26th, 2024 Toronto, Ontario – March 26th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and develo...
Theralase® Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson’s Disease
Press ReleaseV.TLT | February 12th, 2024 Toronto, Ontario – February 12th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and developm...
Dr. Michael Jewett Joins Theralase® to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseV.TLT | February 8th, 2024 Toronto, Ontario – February 8th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and developmen...
Theralase® Closes $CAN 1.2 Million Non-Brokered Private Placement
Press ReleaseV.TLT | February 5th, 2024 Toronto, Ontario – February 5th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and developmen...
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
Press Release, Bladder Cancer, Clinical Study, NMIBCToronto, Ontario – January 15th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or r...
Theralase Release’s 3Q2023 Interim Financial Statements
Press ReleaseToronto, Ontario – November 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/o...
Theralase® Closes $CAN 1.17 Million Non-Brokered Private Placement
Press ReleaseNovember 29, 2023, Theralase® successfully closed a non-brokered private placement offering of units for gross proceeds of approximately $CAN 1,170,000....
Theralase® Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Press ReleaseToronto, Ontario – November 17, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or ...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
